RT Journal Article
SR Electronic
T1 Fine analysis of atypical circulating tumor cells in metastatic breast cancer patients reveals subsets with different prognostic values
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.29.20203653
DO 10.1101/2020.09.29.20203653
A1 Lopresti, Alexia
A1 Boudin, Laurys
A1 Finetti, Pascal
A1 Garnier, Séverine
A1 Aulas, Anaïs
A1 Liberatoscioli, Maria-Lucia
A1 Guille, Arnaud
A1 Dacosta, Quentin
A1 Cabaud, Olivier
A1 Pakradouni, Jihane
A1 Goncalves, Anthony
A1 Birnbaum, Daniel
A1 Bertucci, François
A1 Mamessier, Emilie
A1 Acquaviva, Claire
YR 2020
UL http://medrxiv.org/content/early/2020/09/29/2020.09.29.20203653.abstract
AB Purpose Circulating tumor cells (CTCs) have a tremendous potential for diagnosis and treatment of breast cancer patients. Here, we performed a unique analysis of all atypical circulating cells isolated with a filtration-based technology from metastatic breast cancer (mBC) patients.Patients and methods The PERMED-01 study enrolled patients with mBC, refractory to systemic therapy, and with an accessible lesion to biopsy. We analyzed atypical circulating cells isolated from patients’ blood at the time of inclusion using Screencell® Cyto device. For 23 out of 91 analyzed patients, this was completed by advanced immunofluorescence staining of atypical circulating cells. Subsets cut-offs were established using a two-component Gaussian finite Mixture Model, and evaluated for correlation with clinico-pathological data, including progression-free survival (PFS) and overall survival (OS).Results Three subsets of atypical circulating cells, absent from controls (n=7), were observed in cancer patients (n=91): isolated (iCTCs), Clusters (CTM), and Giant CTCs (gCTCs). CTCs’ median number was 8.33 per mL. Co-expression of stem and drug resistance markers was associated with intermediate epithelial to mesenchymal transition phenotype in CTM and gCTCs, but not in iCTCs. Presence of gCTC was associated with shorter PFS and OS. Concerning PFS, assigning an immunofluorescence-based Epithelial to Mesenchymal status improved their prognostic value.Conclusion This study brings to light the diversity of CTCs in mBC patients and their specific molecular profiles regarding epithelial to mesenchymal transition, stemness and drug resistance status. It also highlights the involvement of an atypical circulating cell subset, the gCTCs, as a prognostic factor for PFS and OS.Competing Interest StatementAG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.Clinical TrialNCT02342158Funding StatementThis work has been supported by Inserm, Institut Paoli-Calmettes (SIRIC INCa-DGOS-Inserm 6038), and grants from the Ligue Nationale Contre Le Cancer (EL2016.LNCC/DaB, EL2019.LNCC/FB), Association Ruban Rose, and Foundation Groupe EDF. AL was supported by the fellowship DOC4 from the Fondation ARC (DOC20180507420). AA was supported by a postdoctoral fellowship from the Fondation ARC (PDF20180507565) and the Fondation de France (00107936). Conflict of Interest: AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National ethics committee (CPP Sud-Mediterranee) registered as identifier NCT02342158 at the ClinicalTrials.gov platformAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on requestmBCmetastatic breast cancerCTCsCirculating Tumor CellsiCTCsisolated Circulating Tumor CellsgCTCgiant Circulating Tumor CellsEM statusEpithelial to Mesenchymal statusEMTEpithelial to Mesenchymal TransitionPFSProgression free survivalOSOverall survivalCTMCirculating tumor microemboliTNTriple NegativeTAMTumor Associated MacrophageCAMLsCancer-Associated Macrophage-Like cells